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Casein kinase II phosphorylation of cyclin F at serine 621 regulates the
Lys48-ubiquitylation E3 ligase activity of the SCF(cyclin F) complex
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that is characterized by progressive
weakness, paralysis and muscle loss often resulting in patient death within 3-5 years of diagnosis. Recently, we
identified disease-linked mutations in the CCNF gene, which encodes the cyclin F protein, in cohorts of
patients with familial and sporadic ALS and frontotemporal dementia (FTD) (Williams KL et al. 2016 Nat.
Commun. 7, 11253. (doi:10.1038/ncomms11253)). Cyclin F is a part of a Skp1-Cul-F-box (SCF) E3
ubiquitinprotein ligase complex and is responsible for ubiquitylating proteins for degradation by the
proteasome. In this study, we investigated the phosphorylation status of cyclin F and the effect of the serine to
glycine substitution at site 621 (S621G) on E3 ligase activity. This specific mutation (S621G) was found in a
multi-generational Australian family with ALS/FTD.We identified seven phosphorylation sites on cyclin F, of
which five are newly reported including Ser621. These phosphorylation sites were mostly identified within the
PEST (proline, glutamic acid, serine and threonine) sequence located at the C-terminus of cyclin F.
Additionally, we determined that casein kinase II (CK2) can phosphorylate Ser621 and thereby regulate the
E3 ligase activity of the SCF(cyclin F) complex. Furthermore, the S621G mutation in cyclin F prevents
phosphorylation by CK2 and confers elevated Lys48-ubiquitylation activity, a hallmark of ALS/FTD
pathology. These findings highlight the importance of phosphorylation in regulating the activity of the
SCF(cyclin F) E3 ligase complex that can affect downstream processes and may lead to defective motor neuron
development, neuron degeneration and ultimately ALS and FTD.
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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that is
characterized by progressive weakness, paralysis and muscle loss often result-
ing in patient death within 3–5 years of diagnosis. Recently, we identified
disease-linked mutations in the CCNF gene, which encodes the cyclin F protein,
in cohorts of patients with familial and sporadic ALS and frontotemporal
dementia (FTD) (Williams KL et al. 2016 Nat. Commun. 7, 11253. (doi:10.1038/
ncomms11253)). Cyclin F is a part of a Skp1-Cul-F-box (SCF) E3 ubiquitin-
protein ligase complex and is responsible for ubiquitylating proteins for
degradation by the proteasome. In this study, we investigated the phosphoryl-
ation status of cyclin F and the effect of the serine to glycine substitution at site
621 (S621G) on E3 ligase activity. This specific mutation (S621G) was found in a
multi-generational Australian family with ALS/FTD. We identified seven phos-
phorylation sites on cyclin F, of which five are newly reported including Ser621.
These phosphorylation sites were mostly identified within the PEST (proline,
glutamic acid, serine and threonine) sequence located at the C-terminus of
cyclin F. Additionally, we determined that casein kinase II (CK2) can phosphor-
ylate Ser621 and thereby regulate the E3 ligase activity of the SCF(cyclin F)
complex. Furthermore, the S621G mutation in cyclin F prevents phosphoryl-
ation by CK2 and confers elevated Lys48-ubiquitylation activity, a hallmark
of ALS/FTD pathology. These findings highlight the importance of phos-
phorylation in regulating the activity of the SCF(cyclin F) E3 ligase complex
that can affect downstream processes and may lead to defective motor
neuron development, neuron degeneration and ultimately ALS and FTD.
1. Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are fatal
neurodegenerative disorders that have common and convergent molecular and
& 2017 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.
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pathogenic features [1]. ALS is characterized by progressive
weakness, paralysis and muscle loss often resulting in patient
death within 3–5 years of diagnosis [2]. Many studies of the
biological mechanisms of ALS and FTD have used in vivo
and in vitro models with genetic mutations found in familial
cases to recapitulate features of the disease. Around 20% of
ALS patients show signs of frontotemporal dementia (FTD)
and segregation of both ALS and FTD may be seen within indi-
vidual families, particularly those with mutations in C9ORF72
[3,4]. Familial ALS cases appear clinically indistinguishable
from sporadic cases [5], and disease models that incorporate
familial gene mutations offer an opportunity to better under-
stand the biology of both familial and sporadic ALS. Genetic
analyses of ALS-affected families have identified mutations
in many genes, including SOD1, TARDBP, FUS, UBQLN2,
VCP, OPTN and C9ORF72 [6–13]. The proteins encoded by
these genes generally cluster into two major functional
groups: RNA/DNA synthesis and processing (e.g. TDP-43
and FUS), and protein degradation pathways (such as
UBQLN2) that lead to proteostasis dysfunction. The link
between protein degradation pathways and ALS and FTD is
additionally supported by the key pathological hallmark of
insoluble proteinaceous inclusions of ubiquitylated proteins,
including TDP-43 [14].
We have recently identified ALS–FTD linked mutations in
the CCNF gene that occur at similar frequency to mutations in
TARDBP [15]. A p.Ser621Gly (S621G) mutation was found to
segregate across multiple generations in an Australian ALS/
FTD family, and mutations in other sites across the protein
were identified in ALS/FTD patients from the USA, Europe
and Japan. Experimental expression of CCNF mutations ident-
ified from ALS/FTD patients led to defective protein
degradation and signature features of ALS pathogenesis
in vitro including elevated ubiquitylation and increased levels
of ubiquitylated ribonucleotide reductase M2 (RRM2) and
TDP-43 [15].
Cyclin F is a part of a Skp1-Cul-F-box (SCF) E3 ubiquitin-
protein ligase complex which is an integral part of a cell’s
recycling system that ubiquitylates substrates for degradation
by the proteasome. Ubiquitylation is carried out in three
main steps: activation by E1s, ubiquitin conjugation by E2s
and substrate ligation by E3s. This sequential cascade is the
tethering of ubiquitin to lysine residues on proteins via differ-
ent ubiquitin linkages (such as lysine 48 (Lys48) or lysine 63
(Lys63)), which in turn directs the tagged protein for various
purposes including signalling and degradation.
There are over 300 known E3 ligases [16], and it has become
increasingly apparent that the activity and substrate selectivity
of many E3 ligases is regulated by other post-translational
modifications, including phosphorylation [17–20], indicating
a convergence of molecular and signalling pathways.
For example, phosphorylation of the C-terminus of mouse
double minute 2 homolog (MDM2) by the kinase ataxia telan-
giectasia mutated (ATM) allosterically inhibits really
interesting new gene (RING) domain oligomerization resulting
in reduced ubiquitylation and stabilization of p53 after DNA
damage [20]. Another example is the phosphorylation of
Smurf1 at Thr306 by protein kinase A, which regulates its sub-
strate preference during axonal development by preventing
degradation of Par6 and increasing degradation of growth-
inhibiting RhoA [19]. In the context of ALS and FTD, it was
recently found that phosphorylation of TDP-43 by truncated
casein kinase (CK) 1d triggers mislocalization and
accumulation of TDP-43 within insoluble aggregates [21],
which are the pathological hallmarks observed in most ALS
and FTD patients [22]. Numerous kinases have been implicated
in TDP-43 phosphorylation including CK1, CK11, CK2, CDC7
and TTBK1/2 [23–27].
In this study, we investigated the phosphorylation status
of cyclin F and the effect of the S621G mutation on its E3
ligase Lys48-specific ubiquitylation activity. We used a
phosphoproteomics workflow to identify several novel phos-
phorylation sites within cyclin F, and identified a key role of
CK2 phosphorylation on Ser621 in regulation of SCF(cyclin F)
E3 ligase activity. These findings provide insights into the
molecular mechanisms of a newly discovered ALS/FTD
gene CCNF, suggesting that the cyclin FS621G mutation affects
Lys48-ubiquitylation activity, with potential consequences for
protein degradation pathways that may drive disease develop-
ment. The convergence of phosphorylation and disease-linked
mutation of a single residue (S621G) indicates that this site is of
particular importance for ALS/FTD.
2. Material and methods
2.1. Reagents
Antibodies used in this study were: rabbit polyclonal anti-cyclin
F (1 : 300; cat# sc-952, Santa Cruz Biotechnology), mouse
monoclonal anti-mCherry (1 : 300; cat# 632543, Clonetech),
rabbit anti-mCherry (cat# ab183628, Abcam), rabbit anti-Skp1
p19 (H-163) (1 : 1000, cat# sc-7163, Santa Cruz Biotechnology),
mouse monoclonal anti-b-tubulin (1 : 2000; cat# T0198, Sigma-
Aldrich) and anti-phospho-CK2 substrate (1 : 1000, cat# 8783,
Cell Signaling Technology). Rabbit antibodies against phospho-
cyclin F (immunogen: DQEpSEGEKEG) and pan-cyclin F
(immunogen: DQESEGEKEG) were customized and purchased
from Bethyl Laboratories. Recombinant casein kinase II was
obtained from New England BioLabs. Plasmid DNA constructs
were purchased from Genscript (Piscataway, NJ, USA)
2.2. Cell culture and transfection
Human embryonic kidney (HEK293) or Neuro-2a cell lines were
plated at 1  106 cells in 100 mm plates and maintained in Dul-
becco’s modified Eagle’s medium (DMEM; Sigma-Aldrich)
supplemented with 10% heat-inactivated fetal bovine serum
(FBS; Sigma-Aldrich) and 1% antibiotics (100 mg ml21 strepto-
mycin and 100 U mL21 penicillin; Sigma-Aldrich) in a 378C
heat-jacket humidified incubator with 5% CO2. Following 48 h
of growth (approx. 80% confluence), HEK293 or Neuro-2a
cells were transfected with DNA constructs as previously
described [15]. Briefly, 7.5 mg of wild-type or mutant cyclin
FS621G cDNA fused to N-terminal mCherry was mixed with
Lipofectamine 2000 (Life Technologies) and Opti-MEM (Life
Technologies) for each plate and incubated at 378C for 5 h.
Cells were washed with warm PBS, re-fed with complete
DMEM media and maintained for 24 h. Transfections were
carried out in three biological replicates from different passages.
For CK2 inhibition, cells were re-fed with complete DMEM
media and treated for 18 h with CX4945 (4 mM) prior to harvest-
ing. For CK2 RNAi knockdowns, 25 pmol of CK2a siRNA I (Cat
#6389, Cell Signaling Technology, MA, USA) was co-transfected
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2.3. Cell lysis and immunoprecipitation
Cells were lysed and total protein was extracted with probe
sonication (10 s, Setting 3, Branson Sonifier 450) in NP40 (1%
(v/v) Nonidet P-40 in TBS (50 mm Tris-HCl, pH 7.5,
150 mm NaCl) or RIPA (1% (v/v) Nonidet P-40, 0.5% (w/v)
sodium deoxycholate, 0.1% (w/v) SDS in TBS) buffer contain-
ing 2 mM EDTA, 10 mM N-ethylmaleimide, Complete
protease inhibitor cocktail (Roche) and PhosStop inhibitor
cocktail (Roche). Cellular debris was pelleted at 16 000g
(30 min at 48C). Protein concentration was estimated using
the Pierce BCA Reagent (Pierce Biotechnology). Typically,
1 mg of antibody per 500 mg of protein extract in NP40 buffer
was used for immunoprecipitations. Protein A/G magnetic
beads (Pierce) were used to capture the antibody : protein com-
plex. Immunoprecipitation mixtures were washed with TBS
containing 1% (v/v) NP40 (3) to remove non-specifically
bound proteins, and then resuspended in either (i) E3 ligase
reaction buffer or (ii) 100 mM ammonium bicarbonate pH 8.0
for in-solution trypsin digestion and LC–MS/MS analyses.
Triplicate immunoprecipitations were carried out from three
biological transfected cell culture replicates.
2.4. One-dimensional SDS-PAGE and immunoblotting
analyses
For one-dimensional SDS-PAGE, denatured proteins (20 mg)
were separated on 4–12% Bis–Tris pre-cast gels using a
3-(N-morpholino) propane sulfonic acid (MOPS) running
buffer (180 V, 125 mA) according to the manufacturer’s
instructions (Invitrogen, MO, USA). One-dimensional SDS-
PAGE separated proteins were transferred onto either nitro-
cellulose or PVDF membranes using the Bio-Rad Turbo
Transfer apparatus (13 V, 1.3 A for 7 min for mini-gels or
25 V, 2.5 A for 10 min for midi-gels). Blots were blocked
with 3% (w/v) skim milk in TBS/T for 1 h and washed in
TBS/T (3). Primary antibodies were diluted in 3% (w/v)
BSA in TBS/T and incubated with blots overnight at 48C.
After incubation, membranes were washed in PBS/T (3)
for 10 min each before fluorescently labelled IRDye 800CW
goat anti-rabbit IgG (1 : 10 000) was applied for 1 h at room
temperature. Proteins were imaged using a Li-Cor Odyssey
imaging system at the appropriate wavelength.
Densitometry analysis was conducted using IMAGEJ software
(v. 1.47; National Institutes of Health) [28] and statistics
were conducted using Microsoft EXCEL. Graphs were made
using GraphPad PRISM 5 and Microsoft EXCEL.
2.5. In vitro phosphorylation by casein kinase II
In vitro phosphorylation of naked DQESEGEKEG peptide
(Synpeptide, Shanghai, China) was carried out according to
the manufacturer’s instructions (New England BioLabs, MA,
USA). Briefly, the naked peptide (0.2 mg) was resuspended in
180.6 ml of MilliQ water (1 nmol ml21). Approximately 0.1
nmol of peptide was added to the reaction buffer (50 mM
Tris-HCl, 10 mM MgCl2, 0.1 mM EDTA, 2 mM DTT, 0.01%
Brij 35, pH 7.5) with recombinant CK2 (250 U) and 400 mM
ATP. The in vitro phosphorylation assay was carried out in
triplicate and incubated at 308C for 2 h. Inhibition of CK2
phosphorylation was carried out in the presence of CX4945
(4 mM). The reaction mixture was stopped by addition
of 2% (v/v) formic acid, desalted using a C18 Sep-Pak and
eluted in 90% ACN, 0.1% formic acid and dried under
vacuum centrifuge.
2.6. Trypsin, Asp-N digestion and titanium dioxide
(TiO2) enrichment
Immunoprecipitated proteins were reduced and alkylated
with 10 mM DTT and 55 mM iodoacetamide respectively,
and digested with trypsin or Asp-N (1 : 50 enzyme : protein)
overnight at 378C. The digestion was inactivated by the
addition of 2 ml of formic acid (final concentration 2% (v/v)
formic acid). Tryptic or Asp-N digested peptides were
cleaned and enriched on a pre-equilibrated C18 Sep-Pak
cartridge and eluted in 90% ACN, 0.1% formic acid and
dried under vacuum centrifugation.
Lyophilized peptides were resuspended in 80 mg ml21
glycolic acid, 80% (v/v) ACN, 5% (v/v) TFA and added to
TiO2 beads (5 mg; GL Sciences, Japan) prewashed in the
same solution [29]. The mixture was incubated for 1 h at
room temperature with mixing at 1400 r.p.m., and centri-
fuged at 800g to recover the beads. The supernatant was
removed and re-added to a fresh batch of TiO2 beads and
repeated. TiO2 beads from both incubations were washed
2 in 80 mg ml21 glycolic acid, 80% (v/v) ACN, 5% (v/v)
TFA, 2 in 80% (v/v) ACN, 1% (v/v) TFA, and 1 in 20%
(v/v) ACN, 0.1% (v/v) TFA. The beads were briefly dried
under vacuum centrifuge. Phosphopeptides were eluted
sequentially with 1% NH4OH, 1% NH4OH/30% ACN and
1% NH4OH/50% ACN. The combined eluates were pooled
and lyophilized under vacuum centrifugation.
2.7. LC – MS/MS
Peptide fractions were injected onto a 2 cm desalting trap
column packed with YMC C18 material (75 mm ID, 5–15 mm,
120 A) at 5 ml min21 for 6 min before being eluted onto an
analytical column packed with Michrom Magic C18 (75 mm 
15 cm, 5 mm, 120 A) using a nanoLC system (Thermo) with a
nanoflow solvent delivery of 300 nl min21. Each sample was
separated on a 60 min gradient (2%–50% v/v acetonitrile,
0.1% formic acid) with a flow rate of 300 nl min21. The peptides
were eluted and ionized into a Q-Exactive or LTQ Orbitrap
Velos mass spectrometer (Thermo Fisher). The electrospray
source was fitted with an emitter tip 10 mm (New Objective,
Woburn, MA) and maintained at 2.5 kV electrospray voltage.
Precursor ions were selected for MS/MS fragmentation using
a data-dependent ‘Top 10’ method operating in FTMS acqui-
sition mode with HCD (Q-Exactive) or CID (Orbitrap)
fragmentation. Precursor ions were selected for MS/MS
fragmentation using a data-dependent ‘Top 10’ method
operating in FT–FT acquisition mode with CID or HCD frag-
mentation. IT-MS and FT-MS on the Orbitrap Velos was
carried out with a survey scan range between m/z 350–1800
Da with MS/MS threshold of 500 ions for CID, and MS/MS
threshold of 5000 ions for HCD, with an isolation width of
2.0 Da and normalized collision energy of 35%.
FT-MS analysis on the Q-Exactive was carried out with a
35 000 resolution and an AGC target of 1  106 ions in full
MS; and MS/MS scans were carried out at 17 500 resolution
with an AGC target of 2  105 ions. Maximum injection
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selection threshold for triggering MS/MS fragmentation was
set to 25 000 counts and an isolation width of 1.9 Da was used
to perform HCD fragmentation with normalized collision
energy of 27%.
Spectra files (*.RAW) were processed using the PROTEOME
DISCOVERER 1.4 software (Thermo Finnigan, CA, USA) incorpor-
ating the Mascot search algorithm (Matrix Sciences, UK).
Peptide identifications were determined using a 10 ppm pre-
cursor ion tolerance and a 0.05 Da MS/MS fragment ion
tolerance. Carbamidomethylation modification of cysteines
was considered a static modification while oxidation of
methionine, acetyl modification on N-terminal residues and
phosphate on serine, threonine and tyrosine were set as varia-
ble modifications. MS/MS spectra were searched through
PROTEOME DISCOVERER (Thermo Scientific) using the Mascot
algorithm against the UniProt Homo sapiens database (sequences
15742024, 7 May 2012). The protein sequence for the mutated
cyclin FS621G was added manually to a custom database which
included the UniProt sequences. The data were processed
through the Xtract and MS2 Processor nodes together with a
direct search and the combined searches were sent to Percolator
(Department of Genome Sciences, University of Washington)
for estimation of false discovery rates. Protein identifications
were validated employing a q-value of 0.01 (1% false-discovery
rate) within the PROTEOME DISCOVERER software. Phosphosite
occupancy was validated using the PhosphoRS 3.1 node
within the PD 1.4 with a fragment mass tolerance of 0.5 Da
[30]. The data has been deposited to the ProteomeXchange
with identifier PXD004531.
2.8. E3 ligase activity assay
E3 ligase activity was determined using the E3LITE Customisa-
ble Ubiquitin Ligase ELISA Kit (LifeSensors, PA, USA) as per
the manufacturer’s instructions. UBE2D3 was selected as the
E2 enzyme and Lys48-ubiqitin was selected as the ubiquitin
substrate. Briefly, empty mCherry vector, mCherry–cyclin F
or pre-immune rabbit control IgG were immunoprecipitated
from transfected HEK293 cells as described above. Protein
A/G beads were washed (3) in 100 mM Tris-HCl (pH 8.0),
10 mM MgCl2 and resuspended in 25 ml assay buffer
(100 mM Tris-HCl, 10 mM MgCl2, 0.2 mM DTT, pH 8.0).
Immunoprecipitated mCherry, mCherry–cyclin FWT,
mCherry–cyclin FS621G and pre-immune rabbit control IgG
200 000
cylin FWT E2 selection for Lys48-ubiquitination E3 ligase assay-phosphatase




















































































































































































Figure 1. SCF(cyclin F) E3 ligase activity is regulated by phosphorylation. E3 ligase activity assays were used to assess the most suitable E2 conjugating enzyme for
mCherry – cyclin F to ubiquitylate substrates. (a) Comparison of four common E2 enzymes (UBE2D3, UBE2L3, UBE2R1 and UBE2E3) found that UBE2D3 was the most
suited and provided the highest conjugation activity for SCF(cyclin F) ( p  0.0001, n ¼ 3, Student’s t-test) followed by UBE2E3 ( p ¼ 0.0131, n ¼ 3). (b) SCF(cyclin F)
was immunoprecipitated from transfected HEK293 cells, treated with Antarctic phosphatase and Lys48-specific E3 ligase activity was measured. The E3 ligase activity
of cyclin FS621G appeared to be more active than the wild-type by approximately 1.3-fold (n ¼ 3, p ¼ 0.0476, one-way ANOVA), and following dephosphoryla-
tion the E3 ligase activity of immunoprecipitated SCF(cyclin F) was significantly reduced in both mutant and wild-type cyclin F respectively by 1.3-fold ( p ¼ 0.0183,
n ¼ 3, one-way ANOVA) and 2.3-fold ( p ¼ 0.0004, n ¼ 3, one-way ANOVA). Data are represented as the mean +s.e.m. using one-way ANOVA with Tukey’s post
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Figure 2. Cyclin F Ser621 is phosphorylated. mCherry – cyclin F from transfected HEK293 cells was immunoprecipitated for phosphorylation analysis (a) MS/MS
spectra of mutated Asp-N digested cyclin F peptide 618DQEGEGEKEG627; (b) MS/MS spectra of Asp-N digested wild-type cyclin F peptide 618DQEpSEGEKEG627; (c)
MS/MS spectra of synthetic cyclin F peptide DQEpSEGEKEG showing almost identical b- and y-ions to the spectra shown in (b); (d ) MS/MS spectra of phosphatase
treated wild-type cyclin F, followed by Asp-N digestion showing complete removal of phosphate prior to MS analysis; and (e) cyclin FWT and cyclin FS621G were
immunoblotted using custom rabbit antibodies raised against DQEpSEGEKEG ( phospho) and DQESEGEKEG ( pan) confirming the phosphorylation status at Ser621 and
reduced phosphorylation by 0.37-fold ( p ¼ 0.0035, n ¼ 3, Student’s t-test).
Table 1. Cyclin F phosphorylation sites. Two digestion strategies: trypsin and Asp-N were used to digest immunoprecipitated mCherry – cyclin F from transfected
HEK293 or Neuro-2a cells. Seven phosphorylation sites were identified, of which five have not been reported and are located within the PEST sequence of
cyclin F. Group-based prediction system (GPS) was used to predict upstream kinases of each phosphorylation site identified.
phosphopeptide sequence start end site predicted upstream kinase
ENpSLQEDR (trypsin) 575 582 S577a AKT
DRGSFVTpTPTAELSSQEETLLGSFL (Asp-N) 581 605 T588a CAMK
DRGSFVTTPpTAELSSQEETLLGSFL (Asp-N) 581 605 T590a CAMK
DQEpSEGEKEG (Asp-N) 618 627 S621a CK2
DVTTSGYSSVSTApSPTSSV (Asp-N) 696 714 S709a P38 MAPK
DVTTSGYSSVSTASPTSpSV (Asp-N) 696 714 S713 P38 MAPK
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were then added to wells containing the Enzyme cocktail (E1
activating enzyme, E2 conjugating enzyme UBE2D3 and recom-
binant Lys48-ubiquitin). Each ligase reaction was activated by
the addition of ATP (0.4 mM) and incubated at RT for 30 min.
Each well was washed with PBS/T (3), incubated with detec-
tion solution 1 for 60 min at RT, followed by incubation with
streptavidin–HRP for 60 min at RT. Luminescence was read
on a FLUOstar OPTIMA reader (BMG Labtech).
3. Results and discussion
In this study, we identified that Ser621 on SCF(cyclin F) was
phosphorylated and required for regulating its Lys48-specific
E3 ligase activity. We determined that phosphorylation at
Ser621 is carried out by CK2, and inhibition of CK2 with
CX4925 blocks phosphorylation at this site and subsequently
elevates SCF(cyclin F) E3 ligase activity. Further, a phosphomi-
metic created by mimicking constitutive phosphorylation of
Ser621 through mutation to an aspartic acid (S621D) led to
reduction in the ubiquitylation activity of cyclin F. Therefore,
phosphorylation at Ser621 appears to act as a signal for
cyclin F to suppress its E3 ligase activity, which can be
regulated by controlling CK2 kinase activity or CK2 gene
expression. Notably, we demonstrate that a recently ident-
ified S621G mutation in cyclin F which causes ALS/FTD
[15] also leads to overactivity in the ubiquitylation activity
of cyclin F, because Ser621 cannot be phosphorylated. The
significance of this finding is that it suggests that abnormal
phosphorylation of Ser621 in cyclin F may perturb cellular
homeostasis leading to abnormal hyperubiquitylation of
proteins, contributing to the aetiology of ALS/FTD.
3.1. The ubiquitylation E3 ligase activity of cyclin F is
regulated by phosphorylation
The SCF(cyclin F) complex is one of the many E3 ligases that are
responsible for ubiquitylating proteins for UPS degradation.
Using a commercial ELISA, we screened for four different E2
conjugating enzymes (UBE2D3, UBE2L3, UBE2R1, UBE2E3)
that promiscuously select a large range of substrates [31]
(figure 1a). Neither UBE2L3 nor UBE2R1 showed Lys48-
ubiquitylation activity, suggesting that these two E2s did
not form the E1–E2–E3 triad with the immunoprecipitated
SCF(cyclin F) complex. UBE2E3 showed E2 Lys48-conjugation
activity approximately twofold above the background (no E2)
(p ¼ 0.0131, n ¼ 3). UBE2D3 showed high Lys48-specific ubi-
quitylation activity and was approximately eightfold higher
than UBE2E3 and 16-fold higher than the background controls
(p  0.0001, n ¼ 3). Based on these data, UBE2D3 was selected
as the E2 conjugating enzyme to be used in downstream E3
ligase activity assays. Immunoblots were carried out following
E3 ligase activity assays to demonstrate equivalent levels of
immunoprecipitated mCherry–cyclin F used for activity
assays (figure 1a).
To determine the E3 ligase activity, wild-type and ALS/
FTD mutant cyclin FS621G were immunoprecipitated from
transfected HEK293 cells, treated with Antarctic phosphatase
to remove phosphate, and the Lys48-specific E3 ligase activity
was measured on bead by ELISA. The E3 ligase activity of
mutant cyclin FS621G was approximately 1.3-fold more active
than wild-type cyclin F (p ¼ 0.0476, n ¼ 3). Given that serine
residues are well-described phosphosites that often regulate
enzymatic activity, this suggests that the phosphorylation of
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Figure 3. Casein kinase II is responsible for phosphorylating Ser621 on cyclin F. (a) MS/MS spectra of synthetic unphosphorylated DQESEGEKEG peptide; (b) MS/MS
spectra of in vitro phosphorylation of synthetic DQEpSEGEKEG peptide by recombinant CK2; (c) MS/MS spectra of in vitro phosphorylation of synthetic DQESEGEKEG
peptide by recombinant CK2 in the presence of 4 mM CX4945 inhibitor; (d ) EIC and matching elution times of m/z 554.2 (unphosphorylated) at 7.6 min and 594.2
( phosphorylated) DQESEGEKEG peptide at 7.9 min demonstrates that both peptides have distinct elution times and provides additional confidence of the existence of
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Figure 4. Casein kinase II phosphorylation regulates SCF(cyclin F) Lys48-specific E3 ligase activity. (a) E3 ligase activity of Lys48-ubiquitylation from immunopreci-
pitated mCherry – cyclin F in transfected cells treated with CX4945 (4 mM) demonstrated elevated ubiquitylation activity with CK2 inhibition by approximately
1.35-fold ( p ¼ 0.0215, n ¼ 3, one-way ANOVA). Immunoblots were carried out following E3 ligase activity assays to demonstrate equivalent levels of
immunoprecipitated mCherry – cyclin F used for activity assays, which also revealed cyclin F contained a CK2 phosphorylation motif. (b) Immunoblot analysis
of phospho-cyclin F (Ser621) using custom antibodies revealed reduced phosphorylation by approximately 0.68-fold ( p ¼ 0.0154, n ¼ 3, one-way ANOVA)
with CX4945 treatment. Vertical dashed line indicates cropped lanes. (c) E3 ligase activity of Lys48-ubiquitylation from immunoprecipitated mCherry – cyclin F
in cells co-transfected with mCherry – CCNFWT or mCherry – CCNFS621G with scramble or CK2 siRNA demonstrated elevated ubiquitylation activity with CK2 knock
down by approximately 1.2-fold ( p ¼ 0.0136, n ¼ 3, one-way ANOVA). Immunoblots were carried out following E3 ligase activity assays to demonstrate equivalent
levels of immunoprecipitated mCherry – cyclin F used for activity assays. (d ) Immunoblot analysis of phospho-cyclin F (Ser621) using custom antibodies revealed
reduced phosphorylation by approximately 0.61-fold ( p ¼ 0.005, n ¼ 3, one-way ANOVA) with CK2 RNAi knockdown. Data are represented as the mean + s.e.m.
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F (and, therefore, loss of this phosphosite through the S621G
mutant increases ubiquitylation activity). Accordingly, follow-
ing complete dephosphorylation the E3 ligase activity of
immunoprecipitated SCF(cyclin F) was significantly decreased
in both mutant and wild-type cyclin F (figure 1b). This effect
was greater in the wild-type (2.3-fold, p ¼ 0.0004, n ¼ 3) than
the mutant cyclin FS621G (1.3-fold, p ¼ 0.0183, n ¼ 3). This led
us to speculate that the activity of the SCF(cyclin F) complex
was regulated by phosphorylation of multiple sites, including
Ser621, which would explain the difference seen in the
decreased activity of wild-type compared with mutant cyclin
FS621G following dephosphorylation. Immunoblots were car-
ried out following E3 ligase activity assays and demonstrated
that the ubiquitylation activity measurements were performed
on equivalent levels of immunoprecipitated mCherry–cyclin F
(figure 1b).
3.2. Identification of phosphosites in cyclin F
The in vitro ubiquitylation assays (figure 1) suggest that Ser621
might be a phosphorylation site that regulates about 30% of
the ubiquitylation activity of cyclin F, which was confirmed
by predictions using NetPhos 2.0 (http://www.cbs.dtu.dk/
services/NetPhos/). NetPhos predicted with high confidence
88 potential phosphorylation sites in cyclin F, which included
Ser621. To determine phosphorylation sites on cyclin F,
transfected mCherry–cyclin F was enriched by immunopreci-
pitation, digested with trypsin, phosphopeptides enriched by
TiO2 beads, and analysed by LC–MS/MS. Using this digestion
procedure, we identified two phosphorylation sites on cyclin F
at Ser577 and Ser754 (table 1). The regions surrounding Ser621
do not contain lysine or arginine residues that are required for
producing appropriate length tryptic peptides for LC–MS.
Instead, we employed Asp-N protease to digest cyclin F,
enriched Asp-N digested peptides using TiO2 and subjected
them to LC–MS/MS. Using this strategy we observed specific
diagnostic ions and loss of phosphate ions (PO4) to detect an
additional four phosphosites on cyclin F: Thr588, Thr590,
Ser621, Ser709 and Ser713 [32] (table 1).
The phosphorylation status of immunoprecipitated
mCherry–cyclin F containing the S621G mutation (figure 2a)
and wild-type mCherry–cyclin FWT (figure 2b) was confirmed
by MS/MS fragmentation. To verify this phosphorylated
sequence, we subjected a synthetic phosphorylated (figure 2c)
and unphosphorylated (not shown) versions of the Asp-N
digested peptide (DQESEGEKEG) to LC–MS/MS. We
confirmed the MS/MS fragmentation spectra matched between
both synthetic and immunoprecipitated peptides. We also
immunoprecipitated mCherry–cyclin F and dephosphorylated
the IP prior to LC–MS/MS analysis and observed MS/MS
fragmentation patterns that were reminiscent of the unpho-
sphorylated version of the peptide (figure 2d), further
confirming that Ser621 is a phosphorylation site. The MS/MS
spectra that confirm the phosphosites described in table 1 are
available on the ProteomeXchange with identifier PXD004531.
Using an alternative method, we examined the phos-
phorylation of cyclin F by immunoblots using customized
antibodies raised against the phosphopeptide sequence DQEp-
SEGEKEG and non-phosphorylated DQESEGEKEG (Bethyl
Laboratories). Although there was very minor non-specific
reactivity observed with the phospho-specific cyclin F anti-
body, we verified that cells expressing only mCherry–cyclin
FWT were phosphorylated at Ser621 with negligible amounts
detected in the mutant cyclin FS621G and empty vector trans-
fected cells (figure 2e). We detected reduced phosphorylation
by approximately 0.37-fold (p ¼ 0.0035, n ¼ 3) of phospho-
specific signal in cyclin FS621G mutant cell lysates compared
with cyclin FWT lysates (figure 2e). We predicted that the
non-phospho-specific antibody would detect less of the
mutant cyclin FS621G than the wild-type cyclin F, and con-
firmed that the antibody reactivity observed was indeed
cyclin F. These data confirm the mass spectrometric identifi-
cation of phosphorylated cyclin F at Ser621. Taken together,
using both trypsin and Asp-N digestion approaches seven
phosphorylation sites were identified, of which five have not
been reported previously (S577, T588, T590, S621, S709) and
two have been previously characterized (S713, S754) [32,33]
(table 1). The phospho-specific antibody to cyclin F was able
to distinguish between phosphorylated wild-type and
mutant cyclin F, and therefore we used this antibody for
further validation to determine the relative level of cyclin F
phosphorylation upon cell treatments.
3.3. Casein kinase II phosphorylates cyclin F at Ser621
Many SCF complexes function by ubiquitylating substrates in a
phosphorylation-dependent manner [34] such that the cyclin-
dependent kinase (CDK) catalytic subunits are used to
phosphorylate substrates and the F-box protein acts as a recep-
tor to recruit phosphorylated substrates to the complex [35].
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Figure 5. Phosphomimetic cyclin FS621D reduces SCF(cyclin F) Lys48-ubiquityla-
tion activity. E3 ligase activity of immunoprecipitated phosphomimetic
mCherry – cyclin FS621D was less active compared with the wild type by
approximately 20% ( p ¼ 0.0326, n ¼ 3, Student’s t-test). Immunoblots
were carried out following E3 ligase activity assays to demonstrate equivalent
levels of immunoprecipitated mCherry – cyclin F used for activity assays.
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ubiquitylated by SCF(FBX4-alphaB crystallin) prior to proteolysis
and is required for regulating cell cycle progression such that
impairment of SCF(FBX4-alphaB crystallin) function attenuates
cyclin D1 ubiquitylation, promoting cyclin D1 overexpression
and accelerated cell-cycle progression [36]. Cyclin F does not
bind CDKs and instead a hydrophobic patch within its cyclin
box domain binds a CY motif (RxL/RxI) in the substrate [37].
Therefore, cyclin F is not phosphorylated by the canonical
series of cyclin-dependent kinases and must be modified
by kinases that are independent of cell-cycle regulation to
ultimately regulate the SCF(cyclin F) complex. Using the
group-based prediction system (GPS) [38], numerous
MAPKs, CDKs and NEKs were identified as potential kinases
that could phosphorylate the newly identified phosphosites in
cyclin F (table 1).
Casein kinase II (CK2) was predicted to phosphorylate
Ser621 with the surrounding sequences falling within the
CK2 substrate motif (S–X–X–D/E). Using the synthetic
naked peptide (DQESEGEKEG) which eluted at 7.6 min
(figure 3a), we performed an in vitro phosphorylation assay
with recombinant CK2 and ATP. The reaction was analysed
by LC–MS/MS, which revealed phosphorylation on serine
within the synthetic peptide that corresponds to Ser621 in
cyclin F that eluted at 7.9 min (figure 3b). We repeated the
in vitro phosphorylation assay in the presence of the CK2
inhibitor CX4945 and analysed the reaction by LC–MS/MS
(figure 3c). Using extracted ion chromatograms (EICs) and
matching retention times of 7.6 and 7.9 min to respecti-
vely identify the unphosphorylated and phosphorylated
peptides and their specific masses, a mixture of 45% naked
DQESEGEKEG peptide (m/z 554.2) and 55% phosphorylated
DQEpSEGEKEG peptide (m/z 594.2) was observed. CX4945
treatment decreased recombinant CK2 phosphorylation activity
by approximately 55% based on area-under-curve measure-
ments (figure 3d). We suspect that the incomplete inhibition
of CK2-mediated phosphorylation of Ser621 by CX4945 was
likely caused by the presence of a 100-fold higher concentration
of ATP than CX4945 (which was required for the in vitro ubiqui-
tylation assay), as CX4945 acts by blocking the ATP-binding site
in CK2 (and therefore CX4945 and ATP are competing for the
same site in CK2) [39]. Attempts to overcome this by perform-
ing the assay with lower concentrations of ATP interfered with
the quality of the ubiquitylation assay (results not shown), and
so we were unable to confirm this experimentally. These results
demonstrate that CK2 can phosphorylate the serine within the
synthetic DQESEGEKEG peptide, corresponding to amino
acids 618–627 of cyclin F. Combined with the bioinformatics
predictions, this provides evidence that CK2 has the ability to
phosphorylate Ser621 within cyclin F in cells.
Next, we examined SCF(CyclinF) E3 ligase activity in the
presence of CK2 inhibition by transfecting HEK293 cells
with cyclin FWT and cyclin FS621G followed by treatment with
CX4945 for 18 h. In cells treated with CX4945, immunopurified
cyclin FWT had approximately 1.35-fold elevated Lys48-ubqiui-
tylation activity compared with the vehicle controls (figure 4a),
while CX4945 treatment did not affect the activity of immuno-
purified mutant cyclin FS621G based on E3 ligase activity assays.
We verified that equivalent levels of immunoprecipitated
mCherry–cyclin F were used in the ubiquitylation assay, by
probing for mCherry and cyclin F at the completion of the E3
ubiquitylation activity assays (figure 4a). We immunoblotted
transfected cell lysates treated with CX4945 using the
phospho-specific cyclin F (Ser621) antibody, and observed
approximately 32% less Ser621 phosphorylation ( p ¼ 0.0154,
n ¼ 3) in CX4945 treated cyclin FWT cells (figure 4b). To confirm
that the CX4945 effectively impairs CK2 activity in these cell-
based assays, we performed immunoblotting analyses to
detect CK2 phosphorylated substrates containing the S–X–
X–D/E motif. Inhibition of CK2 activity by CX4945 resulted
in approximately 39% and 37% decreased phosphorylation of
substrates in cells transfected with cyclin FWT and cyclin
FS621G, respectively. The detection of residual CK2 substrates
in cells treated with CX4945 is likely due to: (i) endogenous













Figure 6. Proposed mechanism of phosphorylated Ser621 in cyclin F and its effect on the SCF(cyclin F) Lys48-ubiquitylation activity. CK2 is responsible for phos-
phorylating Ser621 in cyclin F and regulating the SCF(cyclin F) E3 ligase activity. Inhibition of CK2 activity by either CX4945 or siRNA knock down prevents
phosphorylation of mCherry – cyclin F at Ser621 and elevates its Lys48-specific E3 ligase activity. Additionally, a mutation at Ser621 ( p.Ser621Gly) has been
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treatment because CK2 is constitutively active regulating
numerous cellular processes [40] and/or (ii) incomplete inhi-
bition of CK2 phosphorylation activity by CX4945 as
described earlier (figure 3d).
This finding was recapitulated by siRNA-mediated knock-
down of CK2a expression in cells expressing mCherry–cyclin
FWT and mCherry–cyclin FS621G. In cells expressing cyclin FWT,
with CK2 knockdown, we observed a statistically significant
approximately 20% increase ( p ¼ 0.0136, n ¼ 3) in E3 ligase
activity (figure 4c). We immunoblotted for phospho-specific
cyclin F at Ser621 from transfected cell lysates, and obser-
ved approximately 0.61-fold less Ser621 phosphorylation
( p ¼ 0.005, n ¼ 3) in CK2 RNAi knockdown cells expressing
cyclin FWT compared with those with scramble siRNA control,
further suggesting that CK2 is capable of phosphorylating this
site (figure 4d).
In this study, we predicted and subsequently confirmed
that CK2 phosphorylates Ser621 and, therefore, has a role in
regulating the E3 ligase activity of cyclin F. This is important
because we have recently identified an ALS/FTD-causing
S621G mutation in cyclin F, which presumably prevents phos-
phorylation of Ser621, resulting in elevated activity of cyclin
FS621G that may contribute to the abnormal hyperubiquityla-
tion of proteins, which are a hallmark pathology of ALS and
FTD. This suggests that phosphorylation of Ser621 serves to
turn off cyclin F activity. To confirm this, we generated a
phosphomimetic by mutating Ser621 to an aspartic acid
(S621D). As expected, the phosphomimetic cyclin FS621D was
approximately 0.8-fold less active than the wild-type cyclin F
( p ¼ 0.0367, n ¼ 3) (figure 5). The conversion to an aspartic
acid in place of a phosphorylated serine that is chemically simi-
lar confers a net negative charge rendering this site as being
‘constitutively phosphorylated’, which resulted in a reduction
of E3 ligase activity.
We present a series of biochemical data that collectively
suggest that CK2 phosphorylation of cyclin F at Ser621 is cru-
cial for regulating SCF(cyclin F) complex E3 ligase activity.
Notably, the ALS/FTD-causing S621G missense mutation con-
fers elevated E3 ligase activity (figure 6). Our findings suggest
that precisely regulated phosphorylation of Ser621 in cyclin
F is crucial for the maintenance of appropriate activity of
ubiquitylation-dependent protein degradative pathways.
These pathways are often impaired in neurodegenerative
diseases such as ALS and FTD, indicating that mutation of
Ser621 and altered phosphorylation status of cyclin F is likely
one of the upstream pathogenic causes of these diseases.
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